Liminatus Pharma entered into a subscription agreement with a non-U.S. investor to issue 260,001 shares of common stock at $2.50 per share, generating aggregate gross proceeds of approximately $650,000. The company intends to use the net proceeds for working capital and general corporate purposes. The private placement is expected to close on or about November 20, 2026, with the company agreeing to file a resale registration statement within 60 days of closing. Liminatus Pharma operates in the biopharmaceutical industry, focusing on developing therapies for rare diseases.
